Spis treści:
1. REPORT
2. ESAP METADATE
3. INFORMATION ABOUT THE ENTITY
4. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
1. REPORT
2. ESAP METADATE
3. INFORMATION ABOUT THE ENTITY
4. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
- SFA_Sales_Revenues_June_2026_EN_CORR.rarUpdated preliminary sales revenue data for H1 2026
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 217 | / | 2026 | ||||||||
| Date of issue: | 2026-07-22 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Updated preliminary sales revenue data for H1 2026 | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 2 Ustawy o ofercie – informacje bieї№ce i okresowe | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sofia, Bulgaria, July 22, 2026 – “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) pursuant to the requirements of art. 100t of the Law on Public Offering of Securities (LPOS), announces that for the period from the beginning of 2026, the Company achieved sales growth of 45%, including a 3% decrease in domestic sales and sales growth of 74% in export. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_Sales_Revenues_June_2026_EN_CORR.rar SFA_Sales_Revenues_June_2026_EN_CORR.rar | Updated preliminary sales revenue data for H1 2026 | ||||||||||
| Legal framework | Type of information | ||||
| TRANSD | Inside information | ||||
| RegulatoryData | |||||
| Collection Body | PLKNF | ||||
| Unique data record identifier | |||||
| Type of submission | Correction (to be used when information previously reported is found to be incorrect and should be corrected) | ||||
| Voluntary information flag |  | ||||
| Date or period covered [Date or beginning of the period to which the information relates] | 2026-06-01 | ||||
| Date or period covered [Date or end of the period to which the information relates] | 2026-06-30 | ||||
| Personal data flag | | ||||
| Macierzyste państwo członkowskie, w stosownych przypadkach | PL | ||||
| DocumentReference | |||||
| Język, w którym przekazano informacje | Oryginał (ORIG) czy tłumaczenie (TRAN) | Numer referencyjny pliku danych | |||
| PL | ORIG | ||||
| SubmittingEntity | |||||
| Submitting entity LEI | or | Submitting entity name - natural person | |||
| RelatedEntity/LegalPerson | |||||
| Entity LEI | Size of the entity | Industry sector(s) | |||
| 097900BGGW0000048796 | Large group | (acc. NACE): C | |||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2026-07-22 | Ognian Ivanov Donev | Executive Director | |||
